Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, improving outcomes for many patients. However, toxicities termed immune-related adverse events (irAEs) are limitations of these revolutionary treatments. These irAEs may resolve with treatment or ICI cessation (acute) or persist...
Saved in:
Main Authors: | Douglas B Johnson, Kylie Fletcher |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/12/7/e008591.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Yan Xiao, et al.
Published: (2020-01-01) -
Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors
by: Xinyue Han, et al.
Published: (2025-01-01) -
Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
by: Meriç Dökmetaş, et al.
Published: (2025-01-01) -
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-01-01) -
Resistance mechanisms to immune checkpoint inhibitors: updated insights
by: Besan H. Alsaafeen, et al.
Published: (2025-01-01)